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Abstract
Background: The spontaneous rupture of hepatic metastases is rare compared to that of primary hepatic tumors.
In addition, vemurafenib, a selective inhibitor of the mutant BRAF protein or gene product, has been reported to be
extremely effective in patients with metastatic melanoma who harbor a BRAF V600E mutation.
Case presentation: A 44-year-old female had previously undergone surgery for resection of a malignant melanoma in
the lower right leg. Four years later, hepatic metastases became apparent, and transcatheter arterial embolization (TAE)
was performed. Then she underwent treatment with vemurafenib. The size of the hepatic metastases markedly
decreased. Two months later, they enlarged rapidly and ruptured, requiring emergency TAE. However, the patient
developed hemorrhagic shock and died of renewed intra-abdominal bleeding on the 26th postoperative day.
Conclusions: This is a rare case of ruptured hepatic metastases of malignant melanoma during treatment with
vemurafenib. Postmortem examination and immunohistochemical analysis indicated reactivation of the mitogen-
activated protein kinase pathway in the metastatic tumor, suggesting secondary resistance to vemurafenib as the
possible underlying mechanism.
Background
Hepatic metastases are observed in 68 % of all patients
with malignant melanoma at autopsy [1]. However, few
cases of ruptured hepatic metastases of melanoma have
been reported [2–9]. Recently, it has been reported that
treatment with vemurafenib results in complete or partial
tumor regression in >80 % of melanoma patients with the
BRAF V600E mutation [10]. The following case report
describes a rare complication of ruptured hepatic melan-
oma that occurred during treatment with vemurafenib.
The postmortem examination of the present case may
provide insight into the mechanism underlying this tu-
mor’s secondary resistance to vemurafenib and the subse-
quently fatal rupture.
Case presentation
In August 2008, a 44-year-old female had undergone
surgery for resection of a malignant melanoma in the right
lower leg and a right inguinal metastatic lymph node
(Fig. 1), followed by chemotherapy with doxorubicin,
adriamycin, vincristine, and interferon beta (DAV-feron).
In March 2012, computed tomography (CT) revealed
brain and lung metastases, so the patient began radiation
therapy to treat these lesions.
In September 2012, the patient was admitted to our
hospital for back pain. Abdominal CT and magnetic
resonance imaging detected new multiple hepatic metas-
tases of melanoma. A transcatheter arterial infusion of
cisplatin was administered, and transcatheter arterial
embolization (TAE) was performed. In October 2012, she
began treatment with vemurafenib, based on the finding
of a positive BRAF V600E mutation in the resected pri-
mary site of the skin, which was analyzed by direct se-
quencing analysis using DNA from the paraffin-embedded
primary cutaneous melanoma. She tolerated the treatment
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remarkably well, and the size of the multiple hepatic and
lung metastases decreased, while the size of the brain
metastases did not. In addition, the serum concentration of
5-S-cysteinyldopa (5-S-CD), a biological marker of melan-
oma progression, was also decreased from 40.1 ng/mL to
5.2 ng/mL.
In December 2012, she suddenly developed severe ab-
dominal pain. Abdominal CT revealed ruptured hepatic
metastases accompanied by massive intra-peritoneal
hemorrhage. A retrospective and sequential analysis of the
CT images suggested that a part of the liver metastases
had enlarged rapidly and then ruptured with intratumoral
hemorrhage during vemurafenib treatment (Fig. 2). An
emergency TAE was performed by selective occlusion of
the right hepatic artery using gelatin sponge particles. The
postoperative course was uneventful for several days.
Fig. 1 Gross examination and histologic finding of the cutaneous melanoma. The pigmented skin is located on the lower right leg (black arrow)
(a). The resected specimen contained granular, brown, cytoplasmic pigmented cells (white arrow) (hematoxylin-eosin stain, ×400) (b)
Fig. 2 Sequential images of abdominal computed tomography (CT). These images are from September 2012 (a), November 2012 (b), and
December 2012 (c). There is a metastatic tumor in the right lobe of the liver (a). Initially, the hepatic metastases considerably respond to
vemurafenib treatment, and they become almost invisible (b). Later, they grow rapidly and rupture, resulting in a large amount of free fluid
within the peritoneal cavity surrounding the liver (c). The yellow arrow demonstrates the same tumor in each image
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However, on the 26th postoperative day, she developed
hemorrhagic shock and died of renewed intra-abdominal
bleeding.
An autopsy examination revealed hemoperitoneum
due to rupture of the liver metastases. Metastases were
also discovered in the brain and lungs as well as in the
kidneys, adrenal gland, and lymph nodes, although these
had not been detected on imaging while she was alive.
There was also massive bloody ascites (1700 mL). The
background liver was completely normal, whereas
exposed necrotic tissue and intratumoral hemorrhage
were observed at the site of tumor rupture (Fig. 3). We
concluded that the cause of death was hemorrhagic
shock from ruptured hepatic metastases of malignant
melanoma. Finally, for improved understanding of the
mechanism of refractory metastasis, we conducted an
immunohistochemical analysis of the signal transduction
molecules, phosphorylated extracellular signal-regulated
kinase (p-ERK), and phosphorylated Akt (p-Akt), as well
as the melanocyte marker Melan-A and Ki-67 in tumor
cells of the primary malignant melanoma obtained from
the right lower leg and in hepatic and lymph node
Fig. 3 Cross-sectional and histologic findings of the liver at autopsy. The ruptured region (white asterisk) and subcapsular hematoma surrounding
the liver (white arrow) (a). The metastatic tumor is well demarcated by a fibrous capsule (yellow arrow) (hematoxylin-eosin stain, ×40) (b)
Fig. 4 Microscopic findings of the skin, liver, and lymph node specimen. The skin lesion and the liver and lymph node metastases are stained to
detect Melan-A, Ki-67, phosphorylated extracellular signal regulated kinase, and phosphorylated Akt (×400)
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metastases obtained on autopsy (Fig. 4). Our findings
showed that hepatic and lymph node metastases were
positive for p-ERK and negative for p-AKT, even though
the primary tumor was negative for both.
Conclusions
Compared to primary hepatic tumors, hepatic metasta-
ses that result in spontaneous rupture are rare [6].
Furthermore, only eight reports describing rupture of
hepatic metastases of malignant melanoma have been
published [2–9].
The rupture of hepatic metastases is thought to be
derived from tumor necrosis and increased intra-
abdominal pressure due to straining upon defecation
and forceful palpation [11–13]. In our autopsy case,
gross examination and a microscopic study of the liver
suggested that the increased intratumoral pressure by
rapid growth, acute intratumoral bleeding, and the
subsequent tumor necrosis resulted in rupture (Fig. 3).
The recently developed vemurafenib, a selective inhibi-
tor of the mutant BRAF protein or gene product, has
been reported to be extremely effective in patients with
metastatic melanoma who harbor a BRAF V600E muta-
tion [14–16]. Davies et al. reported that this mutation is
present in approximately 50 % of cutaneous melanoma
cases [16]. In our case, since the BRAF mutation was
positive, we used vemurafenib for treatment, and the
patient was responsive to it. In addition, Anker et al.
described synergistic toxicity from the combination of
radiation and vemurafenib [17], but fortunately, our
patient did not experience complications, such as liver
and skin toxicity, during the course of radiation and
vemurafenib treatment. However, 2 months later, a part
of the hepatic metastasis had enlarged and ruptured with
an increased 5-S-CD.
The clinical course indicated that secondary resist-
ance occurred during treatment with vemurafenib. As
for the mechanism of secondary resistance to vemurafenib,
tumor re-proliferation requires reactivation of the mitogen-
activated protein kinase (MAPK) pathway (intrinsic
pathway) or activation of the phosphatidylinositiol 3-
kinase/AKT/mammalian target of rapamycin (PI3K/AKT/
mTOR) pathway (extrinsic pathway), both of which have
been reported [18, 19]. Therefore, we conducted an immu-
nohistochemical analysis of the signal transduction mole-
cules, p-ERK, and p-Akt, as well as the melanocyte marker
Melan-A and Ki-67 (Fig. 4). Our findings showed that hep-
atic and lymph node metastases obtained on autopsy were
positive for p-ERK and negative for p-AKT, even though
the primary tumor was negative for both. These findings
suggested the strong possibility that reactivation of the
MAPK pathway had occurred without activation of the
PI3K/AKT/mTOR pathway in the hepatic and lymph node
metastases. This type of secondary resistance is thought to
be derived from various causes such as NRAS or MEK
mutations.
This case suggested that secondary resistance of vemur-
afenib, confirmed by an immunohistochemical study, may
cause rapid tumor growth and subsequent rupture. In
addition, immunohistochemical studies may clarify the
mechanism underlying secondary resistance, and they
may provide important information regarding the future
treatment of vemurafenib-resistant metastatic melanoma.
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